JP2006511221A - ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン - Google Patents

ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン Download PDF

Info

Publication number
JP2006511221A
JP2006511221A JP2004563851A JP2004563851A JP2006511221A JP 2006511221 A JP2006511221 A JP 2006511221A JP 2004563851 A JP2004563851 A JP 2004563851A JP 2004563851 A JP2004563851 A JP 2004563851A JP 2006511221 A JP2006511221 A JP 2006511221A
Authority
JP
Japan
Prior art keywords
polynucleotide
hcmv
composition
codon
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004563851A
Other languages
English (en)
Japanese (ja)
Inventor
ジー． ハーマンソン，ゲイリー
ジェイ． ギール，アンドリュー
コプケ ウラック，メアリー
Original Assignee
バイカル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイカル インコーポレイテッド filed Critical バイカル インコーポレイテッド
Publication of JP2006511221A publication Critical patent/JP2006511221A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C07K14/045—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2004563851A 2002-12-23 2003-12-19 ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン Pending JP2006511221A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43554902P 2002-12-23 2002-12-23
PCT/US2003/040685 WO2004058166A2 (en) 2002-12-23 2003-12-19 Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010101904A Division JP5129292B2 (ja) 2002-12-23 2010-04-27 ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン

Publications (1)

Publication Number Publication Date
JP2006511221A true JP2006511221A (ja) 2006-04-06

Family

ID=32682258

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004563851A Pending JP2006511221A (ja) 2002-12-23 2003-12-19 ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン
JP2010101904A Expired - Fee Related JP5129292B2 (ja) 2002-12-23 2010-04-27 ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010101904A Expired - Fee Related JP5129292B2 (ja) 2002-12-23 2010-04-27 ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン

Country Status (12)

Country Link
US (5) US7410795B2 (OSRAM)
EP (2) EP2311848B1 (OSRAM)
JP (2) JP2006511221A (OSRAM)
AT (1) ATE471335T1 (OSRAM)
AU (1) AU2003301148A1 (OSRAM)
CA (2) CA2756797C (OSRAM)
DE (1) DE60333035D1 (OSRAM)
DK (1) DK2311848T3 (OSRAM)
ES (1) ES2429338T3 (OSRAM)
PT (1) PT2311848E (OSRAM)
SI (1) SI2311848T1 (OSRAM)
WO (1) WO2004058166A2 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523086A (ja) * 2007-03-30 2010-07-15 ザ・リサーチ・ファウンデーション・オブ・ステート・ユニヴァーシティー・オブ・ニュー・ヨーク ワクチンに有用な弱毒化ウイルス
WO2011024482A1 (ja) * 2009-08-29 2011-03-03 株式会社バイオメッドコア 抗原特異的ｔ細胞誘導能測定法
JP2018531996A (ja) * 2015-10-22 2018-11-01 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105574B1 (en) * 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
EP1165140B1 (en) * 1999-03-26 2004-08-04 Vical Incorporated Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
WO2004024067A2 (en) * 2002-09-10 2004-03-25 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
JP4917263B2 (ja) * 2002-12-23 2012-04-18 バイカル インコーポレイテッド 核酸／ブロックコポリマー／陽イオン性界面活性剤複合体を凍結乾燥する方法
WO2004058166A2 (en) * 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
JP5390059B2 (ja) * 2002-12-23 2014-01-15 バイカル インコーポレイテッド 無菌ポリヌクレオチド系薬剤の製造方法
EP1607485A1 (en) * 2004-06-14 2005-12-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for quantifying VEGF121 isoform in a biological sample
WO2006060723A2 (en) * 2004-12-03 2006-06-08 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
CN1307423C (zh) * 2005-01-08 2007-03-28 王明丽 重组抗原pp65包被酶标反应板的制法及ELISA检测试剂盒
JP2006223194A (ja) * 2005-02-17 2006-08-31 Tosoh Corp スタニオカルシン１（ＳＴＣ１）ｍＲＮＡの測定方法
CA2598884A1 (en) * 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
WO2007084342A2 (en) 2006-01-13 2007-07-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimi zed il- 15 and il- 15r-alpha genes for expression in mammalian cells
WO2008051285A2 (en) 2006-04-01 2008-05-02 Medical Service Consultation International, Llc Methods and compositions for detecting fungi and mycotoxins
WO2009005917A2 (en) * 2007-05-29 2009-01-08 Vical Incorporated Methods of treating measles infectious disease in mammals
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
CA2728739C (en) 2008-06-20 2017-07-11 Duke University Use of human cytomegalovirus antigens to enhance immune responses to cancer cells
EP2313503A4 (en) * 2008-08-01 2014-01-08 Merck Sharp & Dohme Variant HCMV-PP65, IE1 and IE2 polynucleotides, and uses thereof
US20100068718A1 (en) 2008-08-22 2010-03-18 Hooper Dennis G Methods and Compositions for Identifying Yeast
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
ES2563730T3 (es) 2009-07-15 2016-03-16 Glaxosmithkline Biologicals S.A. Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
US8962251B2 (en) 2009-10-08 2015-02-24 Medical Service Consultation International, Llc Methods and compositions for identifying sulfur and iron modifying bacteria
US8802106B2 (en) * 2009-10-30 2014-08-12 The Administrators Of The Tulane Educational Fund Peptide compositions and methods for inhibiting herpesvirus infection
EP2534164A4 (en) * 2010-02-11 2013-09-11 Intelligent Med Devices Inc OLIGONUCLEOTIDES RELATING TO DIFFICULT CLOSTRIDIUM GENES ENCODING TOXIN B. TOXIN A OR TOXIN BINARY
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
AU2011276234B2 (en) 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CN103327963A (zh) 2010-07-06 2013-09-25 诺华股份有限公司 阳离子水包油乳液
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
PT3981427T (pt) 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
US9127321B2 (en) * 2010-10-06 2015-09-08 The Translational Genomics Research Institute Method of detecting Coccidioides species
TR201903651T4 (tr) 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
SI2707385T1 (en) 2011-05-13 2018-01-31 Glaxosmithkline Biologicals Sa Pregnant RSV F antigens
CA3107288A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
WO2013006842A2 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
TWI570240B (zh) 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
EP2768530A1 (en) 2011-10-11 2014-08-27 Novartis AG Recombinant self-replicating polycistronic rna molecules
US9777043B2 (en) 2011-11-11 2017-10-03 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus
CA2867789C (en) 2012-03-27 2022-06-14 Variation Biotechnologies Inc. Methods for detection of anti-cytomegalovirus neutralizing antibodies
EP2869842A1 (en) 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
NZ704275A (en) 2012-07-11 2016-09-30 Univ Florida Aav-mediated gene therapy for rpgr x-linked retinal degeneration
WO2014055624A1 (en) 2012-10-02 2014-04-10 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
EP2943221A1 (en) 2013-01-10 2015-11-18 Novartis AG Influenza virus immunogenic compositions and uses thereof
EP2765137A1 (en) 2013-02-07 2014-08-13 Sanofi Pasteur Induction of cross-reactive cellular response against rhinovirus antigens
MX2015013013A (es) 2013-03-15 2015-12-01 Applied Food Biotech Inc Receptores felinos del gusto amargo y metodos.
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3556353A3 (en) 2014-02-25 2020-03-18 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2017011773A2 (en) * 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017015463A2 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
MA45209A (fr) 2015-10-22 2019-04-17 Modernatx Inc Vaccins contre les maladies sexuellement transmissibles
MA46080A (fr) 2015-10-22 2019-07-10 Modernatx Inc Vaccins à base d'acide nucléique contre le virus varicelle-zona (vzv)
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
IL264070B2 (en) 2016-07-08 2023-03-01 Univ Pennsylvania Methods and preparations for the treatment of disorders and diseases involving rdh12
US20190314486A1 (en) 2016-10-21 2019-10-17 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
ES2978297T3 (es) 2017-05-17 2024-09-10 Massachusetts Gen Hospital Terapia génica para la esclerosis tuberosa
KR20240096685A (ko) 2017-06-15 2024-06-26 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
AU2019212237B2 (en) 2018-01-29 2024-12-12 Merck Sharp & Dohme Llc Stabilized RSV F proteins and uses thereof
CN109082413B (zh) * 2018-09-18 2023-01-10 四川安可瑞新材料技术有限公司 抗人IgG单克隆抗体、其杂交瘤细胞株及应用
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
JOP20220187A1 (ar) 2020-02-14 2023-01-30 Merck Sharp And Dohme Llc لقاح فيروس الورم الحليمي البشري (hpv)
WO2021222222A1 (en) 2020-04-27 2021-11-04 Mccray Jr Paul B Compositions and methods for the treatment of cystic fibrosis
WO2021224633A1 (en) 2020-05-06 2021-11-11 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
AU2021336217A1 (en) 2020-09-04 2023-04-20 Access To Advanced Health Institute Live-attenuated rna hybrid vaccine technology
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
AU2021335334A1 (en) 2020-09-04 2023-04-20 Access To Advanced Health Institute Genetically-adjuvanted rna vaccines
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
EP4323525A2 (en) 2021-04-16 2024-02-21 Genentech, Inc. Optimized tlr7 ligands and uses thereof
CN117715928A (zh) 2021-06-14 2024-03-15 桥生物基因疗法研究有限责任公司 用于结节性硬化的基因疗法
EP4384195A2 (en) 2021-08-11 2024-06-19 King's College London Compositions and methods for improved treatment of disorders affecting the central nervous system
CN118019547A (zh) 2021-08-19 2024-05-10 默沙东有限责任公司 热稳定脂质纳米粒子及其使用方法
WO2023228116A1 (en) 2022-05-24 2023-11-30 Access To Advanced Health Institute Intranasal administration of thermostable rna vaccines
CA3266697A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN
WO2024068898A1 (en) 2022-09-30 2024-04-04 Centre National De La Recherche Scientifique Therapy by trans-splicing of opa1 pre-messenger rnas for the treatment of diseases associated with opa1 gene mutations
WO2024147114A1 (en) 2023-01-06 2024-07-11 Bloomsbury Genetic Therapies Limited Compositions and methods for treating parkinson's disease
WO2024233425A2 (en) 2023-05-08 2024-11-14 Merck Sharp & Dohme Llc Polynucleotides encoding norovirus vp1 antigens and uses thereof
US20240408188A1 (en) 2023-06-09 2024-12-12 Merck Sharp & Dohme Llc Nanoemulsion adjuvant compositions for human papillomavirus vaccines

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040165A1 (en) * 1996-04-23 1997-10-30 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
JPH11511334A (ja) * 1995-09-22 1999-10-05 ザ ジェネラル ホスピタル コーポレーション 蛋白質の高レベル発現
JP2001509388A (ja) * 1997-07-09 2001-07-24 ザ・ユニバーシティ・オブ・クイーンズランド 標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法
US20020081318A1 (en) * 2000-03-23 2002-06-27 Zaia John A. Protein kinase deficient, immunologically active CMVpp65 mutants
US20020110567A1 (en) * 2000-08-10 2002-08-15 Volker Gerdts In utero oral nucleic acid immunization

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US6242567B1 (en) * 1984-07-27 2001-06-05 City Of Hope Method for detection and prevention of human cytomegalovirus infection
US6133433A (en) 1984-07-27 2000-10-17 City Of Hope Method for detection and prevention of human cytomegalovirus infection
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US6162620A (en) * 1986-03-07 2000-12-19 Cogent Limited Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
US5124440A (en) * 1986-11-24 1992-06-23 The Childrens Hospital, Inc. Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus
US5547834A (en) 1988-01-29 1996-08-20 Chiron Corporation Recombinant CMV neutralizing proteins
DE68929478T2 (de) 1988-01-29 2004-04-29 Aventis Pasteur Rekombinante CMV-Neutralisierungsproteine
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5656611A (en) 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US5837693A (en) 1995-03-24 1998-11-17 The Regents Of The University Of California Intravenous hormone polypeptide delivery by salivary gland expression
US5885971A (en) 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US5721354A (en) * 1995-03-31 1998-02-24 Aviron Human cytomegalovirus DNA sequences
US5800981A (en) * 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
US6020481A (en) 1996-04-01 2000-02-01 The Perkin-Elmer Corporation Asymmetric benzoxanthene dyes
FR2753512B1 (fr) * 1996-09-19 1998-12-31 Sachs Ind Sa Chaine de transmission notamment pour cycle
US6156317A (en) 1996-11-12 2000-12-05 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
KR100239879B1 (ko) * 1997-11-05 2000-02-01 김상조 간암 예방 및 치료용 생약제
JP3253590B2 (ja) * 1998-08-31 2002-02-04 シャープ株式会社 ハーフトーンマスクの製造方法
EP1165140B1 (en) 1999-03-26 2004-08-04 Vical Incorporated Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
FR2804028B1 (fr) 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US6875748B2 (en) 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
EP1156112B1 (en) 2000-05-18 2006-03-01 Geneart GmbH Synthetic gagpol genes and their uses
US20070092526A1 (en) * 2000-06-23 2007-04-26 Evans Robert K Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use
WO2004058166A2 (en) 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US20050283146A1 (en) 2004-06-17 2005-12-22 Lentz David J Thermally extended spiral cryotip for a cryoablation catheter

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11511334A (ja) * 1995-09-22 1999-10-05 ザ ジェネラル ホスピタル コーポレーション 蛋白質の高レベル発現
WO1997040165A1 (en) * 1996-04-23 1997-10-30 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
JP2001509388A (ja) * 1997-07-09 2001-07-24 ザ・ユニバーシティ・オブ・クイーンズランド 標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法
US20020081318A1 (en) * 2000-03-23 2002-06-27 Zaia John A. Protein kinase deficient, immunologically active CMVpp65 mutants
US20020110567A1 (en) * 2000-08-10 2002-08-15 Volker Gerdts In utero oral nucleic acid immunization

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6009055884, Ｎａｔｕｒｅ, 2002, Ｖｏｌ．４１５, ｐ．３３１−３３５ *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523086A (ja) * 2007-03-30 2010-07-15 ザ・リサーチ・ファウンデーション・オブ・ステート・ユニヴァーシティー・オブ・ニュー・ヨーク ワクチンに有用な弱毒化ウイルス
JP2015091247A (ja) * 2007-03-30 2015-05-14 ザ・リサーチ・ファウンデーション・フォー・ザ・ステート・ユニヴァーシティー・オブ・ニュー・ヨーク ワクチンに有用な弱毒化ウイルス
WO2011024482A1 (ja) * 2009-08-29 2011-03-03 株式会社バイオメッドコア 抗原特異的ｔ細胞誘導能測定法
JPWO2011024482A1 (ja) * 2009-08-29 2013-01-24 株式会社バイオメッドコア 抗原特異的ｔ細胞誘導能測定法
JP2018531996A (ja) * 2015-10-22 2018-11-01 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP2021175745A (ja) * 2015-10-22 2021-11-04 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP7278677B2 (ja) 2015-10-22 2023-05-22 モデルナティエックス インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP2023075344A (ja) * 2015-10-22 2023-05-30 モデルナティエックス インコーポレイテッド ヒトサイトメガロウイルスワクチン

Also Published As

Publication number Publication date
JP2010227101A (ja) 2010-10-14
US20080085870A1 (en) 2008-04-10
WO2004058166A2 (en) 2004-07-15
EP1587816A4 (en) 2006-06-07
ES2429338T3 (es) 2013-11-14
DE60333035D1 (de) 2010-07-29
SI2311848T1 (sl) 2013-11-29
US7888112B2 (en) 2011-02-15
CA2756797C (en) 2015-05-05
HK1152945A1 (en) 2012-03-16
US7410795B2 (en) 2008-08-12
AU2003301148A8 (en) 2004-07-22
JP5129292B2 (ja) 2013-01-30
CA2508228A1 (en) 2004-07-15
CA2508228C (en) 2013-12-17
US20110177124A1 (en) 2011-07-21
EP2311848A1 (en) 2011-04-20
PT2311848E (pt) 2013-10-03
EP1587816B1 (en) 2010-06-16
CA2756797A1 (en) 2004-07-15
EP1587816A2 (en) 2005-10-26
EP2311848B1 (en) 2013-07-03
US20130017217A1 (en) 2013-01-17
US9180162B2 (en) 2015-11-10
US8278093B2 (en) 2012-10-02
US20140186382A1 (en) 2014-07-03
US8673317B2 (en) 2014-03-18
WO2004058166A3 (en) 2005-06-16
US20040209241A1 (en) 2004-10-21
DK2311848T3 (da) 2013-10-14
AU2003301148A1 (en) 2004-07-22
ATE471335T1 (de) 2010-07-15

Similar Documents

Publication Publication Date Title
JP5129292B2 (ja) ヒト・サイトメガロウィルス感染に対するコドン最適化型ポリヌクレオチド系ワクチン
US9205146B2 (en) Compositions and methods for vaccinating against HSV-2
HK1152945B (en) Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100622